Quick Takeaways
- Bellevue Group AG filed SCHEDULE 13G for Agios Pharmaceuticals, Inc. Common Stock (AGIO).
- Disclosed ownership: 6.1%.
- Date of event: 01 Jun 2025.
Bellevue Group AG - 01 Jun 2025 SCHEDULE 13G Report for Agios Pharmaceuticals, Inc. Common Stock (AGIO)
- Filing Manager
- Bellevue Group AG
- Reporting Manager
- Bellevue Group AG
- Symbol
- AGIO
- Shares outstanding
- 57,625,410 shares
- Disclosed Ownership
- 3,515,150 shares
- Ownership
- 6.1%
- Form type
- SCHEDULE 13G
- Filing time
- 07 Jul 2025, 19:32:17 UTC
- Date of event
- 01 Jun 2025
- Next filing
- 05 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Bellevue Group AG disclosed 6.1% ownership in Agios Pharmaceuticals, Inc. Common Stock (AGIO) on 01 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 07 Jul 2025, 19:32.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Bellevue Group AG | 6.1% | 3,515,150 | 0 | 3,515,150 | /s/ Stefano Montalbano | Stefano Montalbano/ Chief Financial Officer | |
| Bellevue Asset Management AG | 6.1% | 3,515,150 | 0 | 3,515,150 | /s/ Christoph Eisenring | Christoph Eisenring/ Head Legal & Compliance |